期刊
ACTA PHARMACOLOGICA SINICA
卷 39, 期 11, 页码 1777-1786出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41401-018-0069-8
关键词
defensin; recombinant protein; EGFR-targeting; lidamycin apoprotein; mitochondria-mediated apoptosis; human epidermoid carcinoma A431 cells; human lung carcinoma A549 cells; human lung carcinoma H460 cells
资金
- Significant New Drug Development Major Science and Technology Development Projects of China [2014ZX09201042-003]
- High-Tech Research and Development Program of Shandong Province [2014GSF118022]
- National Natural Science Foundation of China [81502691, 81573246]
- Natural Science Foundation of Shandong Province [ZR2015HM040]
Defensins play an essential role in innate immunity. In this study, a novel recombinant beta-defensin that targets the epidermal growth factor receptor (EGFR) was designed and prepared. The EGFR-targeting beta-defensin consists of an EGF-derived oligopeptide (Ec), a beta-defensin-1 peptide (hBD1) and a lidamycin-derived apoprotein (LDP), which serves as the scaffold for the fusion protein (Ec-LDP-hBD1). Ec-LDP-hBD1 effectively bound to EGFR highly expressed human epidermoid carcinoma A431 cells. The cytotoxicity of Ec-LDP-hBD1 to EGFR highly expressed A431 cells was more potent than that to EGFR low-expressed human lung carcinoma A549 and H460 cells (the IC50 values in A431, A549, and H460 cells were 1.8 +/- 0.55, 11.9 +/- 0.51, and 5.19 +/- 1.21 mu mol/L, respectively); in addition, the cytotoxicity of Ec-LDP-hBD1 was much stronger than that of Ec-LDP and hBD1. Moreover, Ec-LDP-hBD1 suppressed cancer cell proliferation and induced mitochondria-mediated apoptosis. Its in vivo anticancer action was evaluated in athymic mice with A431 and H460 xenografts. The mice were administered Ec-LDP-hBD1 (5, 10 mg/kg, i.v.) two times with a weekly interval. Administration of Ec-LDP-hBD1 markedly inhibited the tumor growth without significant body weight changes. The in vivo imaging further revealed that Ec-LDP-hBD1 had a tumor-specific distribution with a clear image of localization. The results demonstrate that the novel recombinant EGFR-targeting beta-defensin Ec-LDP-hBD1 displays both selectivity and enhanced cytotoxicity against relevant cancer cells by inducing mitochondria-mediated apoptosis and exhibits high therapeutic efficacy against the EGFR-expressed carcinoma xenograft. This novel format of beta-defensin, which induces mitochondrial-mediated apoptosis, may play an active role in EGFR-targeting cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据